Predictors of Stroke Events in Patients with Transient Ischemic Attack Attributable to Intracranial Stenotic Lesions

Toshiyuki Uehara¹, Tomoyuki Ohara¹, Kazuo Minematsu¹, Kazuyuki Nagatsuka² and Kazunori Toyoda¹

Abstract:
Objective The purpose of this study was to identify the predictors of subsequent ischemic stroke events in patients with transient ischemic attack (TIA) attributable to intracranial arterial occlusive lesions.

Methods The study population included 82 patients (55 men; mean age, 69.3±12.1 years) with TIA caused by intracranial arterial occlusive lesions who were admitted to our stroke care unit within 48 h of the onset of a TIA between April 2008 and November 2015. TIA was diagnosed if focal neurological symptoms ascribable to a vascular etiology lasted less than 24 h, irrespective of the presence of ischemic insults on imaging. The primary endpoint was an ischemic stroke event within 90 days of the onset of a TIA.

Results The 90-day risk of ischemic stroke after the onset of a TIA was 14.6% [95% confidence interval (CI): 8.6-23.9%]. Cox proportional hazards multivariate analyses revealed that diffusion-weighted imaging (DWI) positivity [hazard ratio (HR), 8.73; 95%CI, 2.20-41.59; p=0.002], prior ischemic stroke (HR, 4.03; 95%CI, 1.07-15.99; p=0.040), and a high serum level of alkaline phosphatase (ALP) on admission (HR, 1.15; 95%CI, 1.05-1.26; p=0.002, for every +10 U/L) were significant independent predictors of ischemic stroke within 90 days after the onset of a TIA.

Conclusion Our results suggested that patients with a TIA attributable to intracranial artery disease who showed DWI lesions, prior ischemic stroke, or high serum levels of ALP on admission were at high risk of subsequent ischemic stroke events.

Key words: transient ischemic attack, intracranial artery, stenosis

(Intern Med 57: 295-300, 2018) (DOI: 10.2169/internalmedicine.9447-17)
high-density lipoprotein cholesterol (HDL-Chol) <40 mg/dL, low-density lipoprotein cholesterol (LDL-Chol)

sulin or oral hypoglycemic agents), and dyslipidemia [serum

tive 75-g oral glucose tolerance test result, or the use of in-

pheric  ischemic heart disease, hypertension (blood pressure

protocol of the present study.

The following demographic and clinical characteristics of the patients were obtained from a review of our stroke data-

Peripheral venous blood samples were obtained on admission.

ing. The tests included the measurements of the white

It was diagnosed if focal neurological symptoms ascribable to a vascu-

ar cerebral artery, anterior cerebral artery, vertebral artery, basilar artery and posterior cerebral artery. Patients who were diagnosed with cervicocephalic artery disease, other than atherosclerosis (including dissection and cerebral angiti-

s, and patients with potential sources of cardioembolism, such as atrial fibrillation, were excluded from the present study. The ethics committee of the hospital approved the protocol of the present study.

Blood tests

Peripheral venous blood samples were obtained on admission. The tests included the measurements of the white blood cell count, hemoglobin, hematocrit, platelets, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase (ALP), creatinine, total cho-

lesterol (T-Chol), LDL-Chol, HDL-Chol, TG, glucose, high-sensitivity C-reactive protein, and fibrinogen.

Imaging

We used the results of diffusion-weighted imaging (DWI) to evaluate whether acute ischemic lesions were present on admission. The intracranial arteries were estimated by MRA and/or DSA. The degree of occlusive lesions was classified into three grades: moderate (50-69% stenosis), severe (70-99% stenosis), and occlusion. DSA data were used whenever available. The degree of intracranial artery stenosis was estimated according to the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial (17, 18). The grade of in-

tracranial artery stenosis on MRA was identified according to a previously published method (10, 12, 19).

Clinical outcomes

All 82 patients underwent a follow-up examination at 90
days via a direct clinical visit or telephone interview. The outcome measure was the occurrence of ischemic stroke within 90 days of the onset of the TIA. Ischemic stroke was defined by a focal neurological deficit lasting for more than 24 h. Treatments with oral agents (including aspirin, dual antiplatelet therapy, anticoagulant agents, and statins) after the qualifying TIA event were recorded.

Statistical analysis

All of the analyses were performed using the JMP® 10 software program (SAS Institute, Cary, USA). Continuous variables are expressed as the mean ( standard deviation (age, blood pressure on admission, and blood test findings), and as the median and interquartile range (ABCD² score). Categorical data are expressed as percentages. Differences between groups were analyzed using Student’s t test and the Mann-Whitney U test for continuous values and Pearson’s chi-squared test and Fisher’s exact test for categorical vari-

ables, as appropriate. The risk of ischemic stroke after the onset of a TIA was estimated from Kaplan-Meier event-free survival curves. Cox proportional hazards multivariate analyses were performed to identify the predictors of ischemic stroke within 90 days after the onset of a TIA. Sex, age, and variables that showed a p value of <0.10 in a univariate analysis were included in the multivariate analyses. p values
of <0.05 were considered to indicate statistical significance. In the case of blood test findings that showed statistical significance, thresholds were calculated by constructing receiver operating characteristic (ROC) curves.

**Results**

Fig. 1 shows the Kaplan-Meier ischemic stroke-free survival curves. Twelve patients showed subsequent ischemic stroke within 90 days after the onset of a TIA, and ischemic stroke occurred within 2 days after the onset of the TIA in 8 of these 12 patients. The 90-day risk of ischemic stroke after the onset of a TIA was 14.6% [95% confidence interval (CI): 8.6-23.9%]. All 12 infarcts were found in the territory of arteries with occlusive lesions responsible for the neurological symptoms of the qualifying TIA. Cerebral infarctions were detected in the carotid system of 9 patients and in the vertebrobasilar system of 3 patients.

The characteristics of patients with and without ischemic stroke within 90 days after the onset of a TIA are shown in Table 1. Patients with ischemic stroke within 90 days more frequently showed DWI lesions (p=0.0388) and the frequency of prior ischemic stroke among these patients tended to be higher (p=0.0876) in comparison to patients without ischemic stroke. The serum ALP levels on admission of patients with ischemic stroke were significantly higher than those of patients without ischemic stroke (p=0.0020). Fig. 2 shows a comparison of the serum ALP levels on admission of the patients with and without ischemic stroke events after a TIA. The threshold ALP level, calculated by constructing ROC curves, was 292 U/L (area under the curve, 0.76; sensitivity, 58%; specificity, 87%). Table 2 shows the results of the Cox proportional hazards multivariate analyses to identify the predictors of ischemic stroke within 90 days after the onset of a TIA. We used two models: Model 1 included ALP levels for every 10 U/L and Model 2 included ALP levels of ≥292 U/L as variables. Prior ischemic stroke [hazard ratio (HR), 4.37; 95%CI, 1.15-17.31; p=0.030], serum ALP ≥292 U/L on admission (HR, 6.77; 95%CI, 2.10-23.53; p=0.002), and DWI positivity (HR, 7.04; 95%CI, 1.79-31.72; p=0.005) were found to be significant independent predictors of ischemic stroke events.

**Discussion**

The present study demonstrated that the 90-day risk of subsequent ischemic stroke after a TIA attributable to intracranial artery disease was 14.6%. In the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial of high-risk patients with acute TIA or minor stroke, the 90-day stroke risk was 12.5% in patients with intracranial arterial stenosis, while that in patients without intracranial arterial stenosis was 5.4% (14). The results of both our study and the CHANCE trial showed that the risk of recurrent stroke was quite high in patients with TIA or minor stroke who showed symptomatic intracranial artery disease.

This is the first study to find an association between increased serum ALP levels and subsequent ischemic stroke in TIA patients with symptomatic intracranial artery disease. Recent epidemiological studies have demonstrated that ALP elevation was associated with the presence of atherosclerosis in the coronary and peripheral arteries, increased cardiovascular events, and mortality (20, 21). In relation to stroke, a high serum ALP level was associated with the functional outcome and mortality after acute stroke (22, 23). Such findings suggest that increased serum ALP levels may play a pathophysiological role in the development of atherosclerotic vascular disease of the heart and brain (24). ALP might enhance medial calcification and vessel stiffening, and might thus promote atherosclerosis. ALP is also considered to represent a surrogate marker of systemic inflammation, malnutrition, and metabolic syndrome, which may lead to worse clinical outcomes in patients with stroke (22). It is noteworthy that ALP has been shown to be strongly induced by oxidative stress in vascular tissue and bone (25). An autopsy
Table 1. The Characteristics of the Patients with and without Ischemic Stroke within 90 Days after the Onset of a TIA.

|                          | Ischemic stroke within 90 days | p       |
|--------------------------|--------------------------------|---------|
|                          | With (n=12)                     | Without(n=70) |       |
| **Background characteristics** |                                |         |
| Male, n (%)              | 10 (83.3)                      | 45 (64.3)| 0.1945 |
| Age, years, mean (SD)    | 70.7 (10.5)                    | 69.1 (12.4)| 0.6521 |
| **History of**           |                                |         |
| Ischemic stroke, n (%)   | 6 (50.0)                       | 18 (25.7)| 0.0876 |
| Ischemic heart disease, n (%) | 0 (0.0)                      | 8 (11.4)| 0.2177 |
| Hypertension, n (%)      | 8 (66.7)                       | 58 (82.9)| 0.1910 |
| Diabetes mellitus, n (%) | 4 (33.3)                       | 19 (27.1)| 0.6592 |
| Dyslipidemia, n (%)      | 5 (41.7)                       | 41 (58.6)| 0.2756 |
| **Multiple TIA, n (%)    | 3 (25.0)                       | 26 (37.1)| 0.4163 |
| Current smoking, n (%)   | 7 (58.3)                       | 30 (42.9)| 0.2438 |
| Current drinking, n (%)  | 7 (58.3)                       | 30 (42.9)| 0.3195 |
| Premorbid antiplatelet agents, n (%) | 4 (33.3) | 27 (38.6) | 0.7295 |
| **ABCD² score**           |                                |         |
| SBP on admission, mmHg, mean (SD) | 157.5 (34.0)           | 162.0 (23.6)| 0.6777 |
| DBP on admission, mmHg, mean (SD) | 93.1 (18.8)            | 88.8 (22.9)| 0.5095 |
| **Clinical features**    |                                |         |
| Unilateral weakness, n (%) | 10 (83.3)                      | 48 (68.6)| 0.2292 |
| Speech disturbance without weakness, n (%) | 2 (16.7)                  | 8 (11.4)| 0.6420 |
| **Duration of symptoms** |                                |         |
| ≥60 min, n (%)           | 3 (25.0)                       | 19 (27.1)| 0.6420 |
| 10-59 min, n (%)         | 8 (66.7)                       | 36 (51.4)| 0.8056 |
| ABCD² score, median [IQR] | 5 [4, 5.25]                  | 5 [4, 5] | 0.3206 |
| **Blood test findings, mean (SD)** |                          |         |
| White blood cell, x10⁹/μL | 8.2 (3.0)                     | 7.1 (2.5)| 0.2568 |
| Hemoglobin, g/dL         | 14.4 (2.0)                     | 13.4 (18.1)| 0.1206 |
| Hematocrit, %            | 43.0 (6.5)                     | 39.8 (4.9)| 0.1235 |
| Platelets, x10⁹/μL       | 232.8 (129.5)                  | 223.2 (62.3)| 0.8056 |
| Albumin, g/dL            | 4.3 (0.4)                      | 4.2 (0.5)| 0.4878 |
| Aspartate aminotransferase, U/L | 25.5 (6.9)                   | 23.8 (9.3)| 0.4553 |
| Alanine aminotransferase, U/L | 22.1 (10.9)                | 18.5 (10.3)| 0.3004 |
| γ-glutamyl transpeptidase, U/L | 33.4 (15.8)              | 42.2 (74.5)| 0.3813 |
| Lactate dehydrogenase, U/L | 246.2 (86.5)                 | 212.9 (76.1)| 0.4161 |
| Alkaline phosphatase (ALP), U/L | 283.7 (67.8)              | 223.1 (59.2)| 0.0020 |
| Creatinine, mg/dL        | 0.96 (0.43)                    | 0.91 (0.41)| 0.7124 |
| Total cholesterol, mg/dL | 202.1 (53.7)                  | 194.9 (39.4)| 0.6656 |
| LDL-cholesterol, mg/dL   | 126.3 (40.7)                  | 116.5 (37.5)| 0.4517 |
| HDL-cholesterol, mg/dL   | 45.9 (10.9)                   | 51.4 (15.7)| 0.1527 |
| Triglyceride, mg/dL      | 169.1 (136.1)                 | 157.6 (141.0)| 0.7822 |
| Glucose, mg/dL           | 144.9 (58.2)                  | 127.3 (36.2)| 0.3305 |
| Hemoglobin A1c, %        | 6.6 (2.0)                     | 6.1 (0.8)| 0.4085 |
| hsCRP, mg/dL, median [IQR] | 0.04 (0.0225, 0.14)         | 0.07 (0.03, 0.19)| 0.2776 |
| Fibrinogen, mg/dL        | 305.5 (61.0)                  | 327.4 (74.9)| 0.3018 |
| D-dimer, mg/mL, median [IQR] | 0.9 [0.525, 1.4]        | 0.8 [0.5, 1.5]| 0.9155 |
| **Imaging findings**     |                                |         |
| Grade of occlusive lesions |                                |         | 0.7290 |
| Moderate, n (%)          | 3 (25.0)                       | 25 (35.7)|         |
| Severe, n (%)            | 7 (58.3)                       | 37 (52.9)|         |
| Occluded, n (%)          | 2 (16.7)                       | 8 (11.4)|         |
| DWI lesions, n (%)       | 7 (58.3)                       | 18 (25.7)| 0.0388 |
| **Acute treatment with oral agents** |                        |         |
| Aspirin, n (%)           | 11 (91.7)                      | 63 (90.0)| 0.8573 |
| Dual antiplatelet therapy, n (%) | 3 (25.0)                  | 37 (52.9)| 0.1172 |
| Anticoagulant, n (%)     | 0 (0.0)                        | 0 (0.0)|         |
| Statin, n (%)            | 6 (50.0)                       | 45 (64.3)| 0.3457 |

TIA: transient ischemic attack, SD: standard deviation, SBP: systolic blood pressure, DBP: diastolic blood pressure, IQR: interquartile range, LDL: low-density lipoprotein, HDL: high-density lipoprotein, hsCRP: high-sensitivity C-reactive protein, DWI: diffusion-weighted imaging
study revealed that intracranial arteries were susceptible to oxidative stress and predisposed to respond with accelerated atherogenesis when antioxidant protection was decreased (26). The results of our study may indicate that an increased serum ALP level is a surrogate marker for vulnerability to symptomatic intracranial artery disease in patients with TIA. In contrast to our findings, however, two previous studies found that an increased serum level of ALP was not associated with the presence or severity of intracranial arterial stenosis (22, 24). Larger studies are needed to confirm our findings.

DWI positivity is a well-known predictor of ischemic stroke after TIA. In the WASID trial, which enrolled patients who had experienced a TIA or nondisabling stroke within the preceding 3 months and who showed 50-99% stenosis of a corresponding major intracranial artery on angiography, the presence of cerebral infarction on baseline neuroimaging was the only statistically significant predictor of a higher risk of early stroke (18). The results of our study confirmed DWI positivity as a predictor of subsequent stroke in TIA patients with symptomatic intracranial artery disease.

We found that prior ischemic stroke was a significant independent predictor of ischemic stroke after TIA. Kernan et al. reported that prior stroke was a predictor of recurrent stroke after a TIA or stroke (27). In the PROMAPA study—a multicenter prospective TIA registry operating from 30 Spanish centers—prior stroke and coronary heart disease were independent predictors of late (from 7 days to 1 year after the onset of a TIA) recurrent stroke after a TIA (28).

Our study is associated with several limitations. First, the sample size was too small to avoid type 1 and 2 errors. Second, we only analyzed inpatients with TIA using a retrospective design, which might have led to a selection bias. However, most TIA patients were hospitalized for urgent work-up and treatment in our unit if they presented to the hospital within 48 h after the onset of a TIA. Thus, our study patients were essentially consecutive cases. Finally, this study was conducted in a single center. These findings should be confirmed in a large multicenter setting to determine if they can be generalized.

In conclusion, our results suggested that patients with TIA attributable to intracranial artery disease who had DWI lesions, prior ischemic stroke, and a high serum level of ALP on admission were at high risk of subsequent ischemic

Table 2. The Results of the Cox Proportional Hazard Multivariate Analyses of Variables Associated with Ischemic Stroke within 90 Days after the Onset of a TIA.

|                      | Model 1 |         | p      | Model 2 |         | p      |
|----------------------|---------|---------|--------|---------|---------|--------|
|                      | HR      | 95%CI   |        | HR      | 95%CI   |        |
| Male                 | 1.47    | 0.34-10.20 | 0.634 | 1.37    | 0.32-9.37 | 0.690 |
| Age (for every 10 years) | 1.15   | 0.64-2.82 | 0.473 | 1.25    | 0.62-2.65 | 0.535 |
| Prior ischemic stroke | 4.03    | 1.07-15.99 | 0.040 | 4.37    | 1.15-17.31 | 0.030 |
| ALP (for every +10 U/L) | 1.15  | 1.05-1.26 | 0.002 | 6.77    | 2.10-23.53 | 0.002 |
| ALP ≥292 U/L         | 8.73    | 2.20-41.59 | 0.002 | 7.04    | 1.79-31.72 | 0.005 |

TIA: transient ischemic attack, HR: hazard ratio, CI: confidence interval, ALP: alkaline phosphatase, DWI: diffusion-weighted imaging

Figure 2. The serum alkaline phosphatase levels on admission in patients with and without ischemic stroke events within 90 days after the onset of a TIA. Boxes represent the interquartile range. Lines in boxes indicate the median values. Whiskers represent the 10th and 90th percentile values. TIA: transient ischemic attack
stroke events.

The authors state that they have no Conflict of Interest (COI).

Financial Support
This study was supported in part by Grants-in-Aid (H21-Junkanki-Ippan-019 and H24-Junkanki-Ippan-011) from the Ministry of Health, Labour and Welfare of Japan (MHLW-Japan) and JSPS KAKENHI Grant Number 24591309.

References

1. Sheehan OC, Kyne L, Kelly LA, et al. Population-based study of ABCD² score, carotid stenosis, and atrial fibrillation for early stroke prediction after transient ischemic attack. The North Dublin TIA Study. Stroke 41: 844-850, 2010.
2. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Varez-Sabin J. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to attack subtypes. Stroke 38: 3225-3229, 2007.
3. Poisson SN, Nguyen-HuyHN MN, Johnston SC, Furie KL, Lev MH, Smith WS. Intracranial large vessel occlusion as a predictor of decline in functional status after transient ischemic attack. Stroke 42: 44-47, 2011.
4. Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD. Calgary Stroke Program CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke 43: 1013-1017, 2012.
5. Siyi-Yan-Kai G, Nasr N, Faury A, et al. Intracranial artery stenosis or occlusion predicts ischemic recurrence after transient ischemic attack. AJNR Am J Neuroradiol 34: 185-190, 2013.
6. Purroy F, Jiménez-Caballero PE, Mauri-Capdevila G, et al. PRO-MAPA study: Stroke Project, Cerebrovascular Diseases Study Group, Spanish Neurological Society. Predictive value of brain and vascular imaging including intracranial vessels in transient ischemic attack patients: external validation of the ABCD3-I score. Eur J Neuro 20: 1088-1093, 2013.
7. Toda T, Kamouchi M, Kunii Y, et al. ABCD3 and ABCD3-I score are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 45: 418-425, 2014.
8. Kobayashi J, Uehara T, Toyoda K, et al. Clinical significance of fluid-attenuated inversion recovery vascular hyperintensities in TIA. Stroke 44: 1635-1640, 2013.
9. Amarenco P, Lavallée PC, Labreuche J, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 374: 1533-1542, 2016.
10. Uehara T, Tabuchi M, Hayashi T, Kurogane H, Yamadori A. Asymptomatic occlusive lesions of carotid and intracranial arteries in Japanese patients with ischemic heart disease: evaluation by brain magnetic resonance angiography, Stroke 27: 393-397, 1996.
11. Minematsu K, Bang O, Uehara T. Risk factors. In: Intracranial atherosclerosis. 1st ed. Kim JS, Caplan LR, Wong KS, Eds, Wiley-Blackwell, UK, 2008: 45-54.
12. Uehara T, Tabuchi M, Mori E. Frequency and clinical correlates of occlusive lesions of cerebral arteries in Japanese patients without stroke: evaluation by MR angiography. Cerebrovasc Dis 8: 267-272, 1998.
13. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45: 2160-2236, 2014.
14. Liu L, Wong KS, Leng X, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology 85: 1154-1162, 2015.
15. Uehara T, Ohara T, Toyoda K, Nagatsu k, Minematsu K. Clinical, laboratory, and imaging characteristics of transient ischemic attack caused by large artery lesions: a comparison between carotid and intracranial arteries. Cerebrovasc Dis Extra 5: 115-123, 2015.
16. Johnston SC, Rothwell PM, Nguyen-HuyHN MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369: 283-292, 2007.
17. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352: 1305-1316, 2005.
18. Ovbiagele B, Cruz-Flores S, Lynn MJ, Chimowitz MI. Early stroke risk after transient ischemic attack among individuals with symptomatic intracranial artery stenosis. Arch Neurol 65: 733-737, 2008.
19. Uehara T, Mori E, Tabuchi M, Ohsumi Y, Yamadori A. Detection of occlusive lesion in intracranial arteries by three-dimensional time-of-flight magnetic resonance angiography, Cerebrovasc Dis 4: 365-370, 1994.
20. Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol 33: 1070-1076, 2013.
21. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120: 1784-1792, 2009.
22. Kim J, Song TJ, Song D, et al. Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction. Stroke 44: 3547-3549, 2013.
23. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke. Neurology 75: 1995-2002, 2010.
24. Lee HB, Kim J, Kim SH, Kim S, Kim OJ, Oh SH. Association between serum alkaline phosphatase level and cerebral small vessel disease. PLoS One 10: e0143355, 2015.
25. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 15: 509-519, 2001.
26. D’Armentio FP, Bianchi A, Nigris F, et al. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke 32: 2472-2479, 2001.
27. Kornan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 31: 456-462, 2000.
28. Purroy F, Jiménez-Caballero PE, Gorospe A, et al. How predictors and patterns of stroke recurrence after a TIA differ during the first year of follow-up. J Neurol 261: 1614-1621, 2014.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).